[HTML][HTML] Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
N Ioannou, AG Dalgleish, AM Seddon… - British journal of …, 2011 - nature.com
Background: The combination of the reversible epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) erlotinib with gemcitabine obtained FDA approval for treating …
tyrosine kinase inhibitor (TKI) erlotinib with gemcitabine obtained FDA approval for treating …
Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS …
F Huguet, M Fernet, N Giocanti, V Favaudon… - Targeted …, 2016 - Springer
Background Pancreatic adenocarcinoma is characterized by a high frequency of KRAS
mutations and frequent deregulation of the epidermal growth factor receptor (EGFR) and …
mutations and frequent deregulation of the epidermal growth factor receptor (EGFR) and …
Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of …
SA Khelwatty, S Essapen… - International …, 2011 - spandidos-publications.com
Despite the approval of the anti-epidermal growth factor receptor (EGFR) monoclonal
antibodies (mAbs), cetuximab and panitumumab, for the treatment of colorectal cancer …
antibodies (mAbs), cetuximab and panitumumab, for the treatment of colorectal cancer …
[HTML][HTML] Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human …
N Ioannou, AM Seddon, A Dalgleish, D Mackintosh… - BMC cancer, 2013 - Springer
Background Aberrant expression and activation of the IGF-IR have been reported in a
variety of human cancers and have been associated with resistance to HER targeted …
variety of human cancers and have been associated with resistance to HER targeted …
[HTML][HTML] A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
H Modjtahedi, BC Cho, MC Michel, F Solca - … -Schmiedeberg's archives of …, 2014 - Springer
Afatinib (also known as BIBW 2992) has recently been approved in several countries for the
treatment of a distinct type of epidermal growth factor receptor (EGFR)-mutated non-small …
treatment of a distinct type of epidermal growth factor receptor (EGFR)-mutated non-small …
Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours
S Wind, M Schmid, J Erhardt, RG Goeldner… - Clinical …, 2013 - Springer
Abstract Background and Objective Afatinib is a potent, irreversible, ErbB family blocker in
clinical development for the treatment of a variety of solid tumours. This study evaluated the …
clinical development for the treatment of a variety of solid tumours. This study evaluated the …
[HTML][HTML] A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours
A Suder, JE Ang, F Kyle, D Harris, S Rudman… - European Journal of …, 2015 - Elsevier
Background This phase I study evaluated afatinib, an irreversible ErbB family blocker, plus
paclitaxel in patients with advanced solid tumours likely to express human epidermal growth …
paclitaxel in patients with advanced solid tumours likely to express human epidermal growth …
[HTML][HTML] A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus …
JB Vermorken, S Rottey, E Ehrnrooth, K Pelling… - Annals of oncology, 2013 - Elsevier
Abstract Background In this phase Ib, dose-escalation study, the oral irreversible ErbB family
blocker afatinib (BIBW 2992) was combined with cisplatin (Cadila Healthcare Ltd …
blocker afatinib (BIBW 2992) was combined with cisplatin (Cadila Healthcare Ltd …
Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker
F Solca, G Dahl, A Zoephel, G Bader… - … of Pharmacology and …, 2012 - ASPET
Deregulation of the ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H strain)
receptor network is well recognized as an oncogenic driver in epithelial cancers. Several …
receptor network is well recognized as an oncogenic driver in epithelial cancers. Several …
Preclinical antitumor activity of S‐222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor …
H Tanaka, M Hirata, S Shinonome, T Wada… - Cancer …, 2014 - Wiley Online Library
Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2
(HER 2) are validated molecular targets in cancer therapy. Dual blockade has been …
(HER 2) are validated molecular targets in cancer therapy. Dual blockade has been …